Showing 4711-4720 of 8165 results for "".
- Navigating the Ins and Outs of Your Insurance Coverage During COVID-19https://practicaldermatology.com/news/navigating-the-ins-and-outs-of-your-insurance-coverage-during-covid-19-1/2460349/Jason O’Dell, a financial consultant and insurance specialist at OJM Group, spoke with New Jersey-based dermatologist Jeanine Downie, MD and Chicagoland facial plastic surgeon Steve Dayan, MD about what to expect from insurance coverage during the pandemic and how to beef up your policies i
- Industry Responds to COVID-19: E.T. Browne Drug Co., Columbia University Medical Center, RealSelfhttps://practicaldermatology.com/news/industry-responds-to-covid-19-et-browne-drug-co-realself-hydrafacial-thrive-causemetics/2460345/E.T. Browne Drug Co. The manufacturer of Palmer' Cocoa Butter Formula and Coconut Oil Formula skin and hair care products is now producing medical-grade hand sanitizer to address widespread supply shortages in the wake of COVID-19. Initial production of the disinfectant sanit
- Cynosure Names David Long Global Chief Financial Officerhttps://practicaldermatology.com/news/cynosure-names-david-long-global-chief-financial-officer/2460343/David Long is Cynosure’s new Chief Financial Officer, effective immediately. Until recently, Long served as CFO at Corindus Vascular Robotics, Inc., where he brought the company public and, ultimately, navigated its strategic sale to Siemens.
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir
- Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for Psoriasishttps://practicaldermatology.com/news/dermavant-completes-patient-enrollment-for-two-phase-3-clinical-trials-of-tapinarof-for-psoriasis/2460339/Dermavant Sciences completed patient enrollment in PSOARING 1 and PSOARING 2 clinical trials of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA), in adult patients diagnosed with plaque psoriasis. Dermavant expects t
- Dupixent Significantly Improves Severe AD in Childrenhttps://practicaldermatology.com/news/dupixent-significantly-improves-severe-ad-in-children/2460338/Dupixent showed significant improvement in severe atopic dermatitis (AD) for children aged 6 to 11 Years, according to a Phase 3 study. In the trial, Dupixent combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related q
- Antimalarials for COVID-19: Will Demand Outweigh Supply?https://practicaldermatology.com/news/antimalarials-for-covid-19-will-demand-outweigh-supply/2460337/Chloroquine and hydroxychloroquine may help treat COVID-19, but if mass prophylaxis is advised it's possible that demand will outweigh the supply of antimalarials, say Italian doctors in a letter published online today in the Annals of the Rheumatic Diseases. The results of prelimin
- New UAB Infographic Depicts How Long COVID-19 Lasts on Surfaceshttps://practicaldermatology.com/news/new-uab-infographic-depicts-how-long-covid-19-lasts-on-surfaces-1/2460336/A virologist and an infectious diseases physician at the
- Wontech Scores FDA Nod for Sandro Dual Laserhttps://practicaldermatology.com/news/wontech-scores-fda-nod-for-sandro-dual-laser/2460333/The U.S. Food and Drug Administration granted 510 (K) marketing clearance to Wontech’s Sandro Dual, a hybrid Nd:YAG & Alexandrite laser device. In the hybrid mode, by irradiating a short time difference between two wavelengths of 755nm and 1064nm, the laser accurately hits its
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant